Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
Phone+1-250-7084272
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$466,000.00
Profitability
Miscellaneous
Employees33
OptionableNot Optionable
Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."
When is Aurinia Pharmaceuticals' next earnings date?
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News stories about AUP stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Computer Modelling Group (CMG), Absolute Software (ABT), TECSYS (TCS), 99 Wuxian (NNW), iSentia Group (ISD), LeoNovus (LTV), Smart Parking (SPZ), Sensen Networks (SNS), NexJ Systems (NXJ), Western Resources (WRX), VIQ Solutions (VQS), Totally Hip Technologies (THP), Covata (CVT) and Labrador Technologies (LTX).
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUP stock can currently be purchased for approximately C$8.30.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of C$709.65 million and generates C$466,000.00 in revenue each year. Aurinia Pharmaceuticals employs 33 workers across the globe.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
